News & Events about Myriad Genetics Inc.
Myriad Genetics continues to advance non-invasive prenatal screening with Prequel and the forthcoming FirstGene test using AMPLIFY technology SALT LAKE CITY, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced ...
SALT LAKE CITY, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Paul J. Diaz, president and chief executive officer, and Dale Muzzey, chief scientific officer, will present at the 41st Annual J.P. Morgan (...
Myriads MyRisk Hereditary Cancer test with RiskScore provides a personalized breast cancer risk assessment for women of all ancestriesSALT LAKE CITY, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc.(NASDAQ: MYGN), a leader in genetic testing and precision medicine, today presented results ...
Globe Newswire
3 months ago
$67.5 million tuck-in acquisition strengthens Myriads Womens Health portfolio of prenatal productsFast-growing SneakPeek test has helped 750,000 parents learn babys gender from home earliest method to date at 6 weeks into pregnancy SALT LAKE CITY, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, ...
Globe Newswire
3 months ago
Highlights: Revenue of $156.4 million for the quarter ended September 30, 2022. Third quarter revenue, excluding divested businesses, was impacted by currency translations ($3.3 million), change of estimates1 ($5.3 million). Third quarter testing volumes, excluding divested businesses, grew 12% year...